Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed Jul 27, 2022
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Award
Ordinary Shares
2022-07-25+20,000→ 499,183 total
Footnotes (1)
- [F1]On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service.